Beacon Biomedical Inc. to Present at Singular Research Spring Select "Best of the Uncovereds" Investment Conference on June 9, 2016

PHOENIX - June 2, 2016 - PRLog -- Beacon Biomedical, Inc., a privately held company focused on developing highly accurate laboratory and point-of-care blood tests for colorectal cancer screening and early detection, announced today that it will present at the Angel Launch and Singular Research's "Best of the Uncovereds" Investor Conference. The conference is being held on June 9, 2016 at the Hilton San Francisco - Financial District.

Donald Weber, Beacon's Chief Executive Officer, stated, "This Spring Select Investment Conference showcases firms that are off-radar but are considered among the best of the uncovered companies positioned for explosive growth. So, we're extremely pleased to be presenting at this event."

Beacon has reached some significant milestones with its BeScreened™-CRC colorectal cancer screening test having demonstrated in its initial clinical data 95% accuracy across all patient demographics. Prior to and following the meeting, management will be available to meet with investors in one-on-one breakout meetings at the conference.

For more conference information, please visit www.singularresearch.com/featured/singular-research-san-francisco-spring-select-conference. A live webcast of this presentation will be available on the Singular Research web site at www.singularresearch.com/webcast/. A replay of the webcast will also be available for approximately two weeks on the Singular Research web site.

About Beacon Biomedical, Inc.

Beacon Biomedical, Inc. is a privately held assay development and medical device company focused on developing and commercializing easy, accurate and affordable colorectal, breast and lung cancer screening solutions. Additional information about Beacon Biomedical is available at http://www.beaconbiomedical.com.